An Immunogenicity and Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years.
Latest Information Update: 09 May 2022
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Cervical cancer; Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme Corp.
- 17 Mar 2012 Results published in Vaccine.
- 17 Nov 2009 Official Title and inclusion/exclusion amended as reported by ClinicalTrials.gov.
- 17 Nov 2009 Official Title and inclusion/exclusion amended as reported by ClinicalTrials.gov.